ALNY | Alnylam Pharmaceuticals, Inc.

Index- P/E- EPS (ttm)-8.70 Insider Own0.10% Shs Outstand124.11M Perf Week-1.47%
Market Cap23.15B Forward P/E- EPS next Y-2.47 Insider Trans-27.07% Shs Float122.39M Perf Month-9.55%
Income-1064.90M PEG- EPS next Q-1.53 Inst Own97.20% Short Float / Ratio4.18% / 7.06 Perf Quarter4.47%
Sales1.14B P/S20.25 EPS this Y-29.10% Inst Trans0.99% Short Interest5.12M Perf Half Y-17.51%
Book/sh-2.09 P/B- EPS next Y59.90% ROA-30.90% Target Price249.95 Perf Year36.89%
Cash/sh17.07 P/C11.18 EPS next 5Y- ROE- 52W Range122.57 - 242.97 Perf YTD-19.70%
Dividend- P/FCF- EPS past 5Y-11.40% ROI-100.80% 52W High-21.46% Beta0.48
Dividend %- Quick Ratio3.60 Sales past 5Y63.10% Gross Margin83.60% 52W Low55.69% ATR5.17
Employees2002 Current Ratio3.80 Sales Q/Q49.70% Oper. Margin-75.60% RSI (14)45.54 Volatility1.84% 2.72%
OptionableYes Debt/Eq- EPS Q/Q29.70% Profit Margin-93.10% Rel Volume0.51 Prev Close190.43
ShortableYes LT Debt/Eq- EarningsMay 04 BMO Payout- Avg Volume725.59K Price190.83
Recom1.90 SMA20-0.80% SMA50-4.05% SMA200-8.46% Volume373,397 Change0.21%
Date Action Analyst Rating Change Price Target Change
May-05-23Upgrade BMO Capital Markets Market Perform → Outperform $200 → $250
Apr-26-23Initiated SMBC Nikko Neutral $220
Mar-21-23Initiated Bernstein Outperform $243
Jan-18-23Initiated Canaccord Genuity Buy $310
Sep-09-22Resumed Morgan Stanley Equal-Weight $222
Jul-13-22Initiated Cantor Fitzgerald Neutral $175
Jun-27-22Downgrade Guggenheim Buy → Neutral
Jun-07-22Initiated William Blair Outperform
Apr-25-22Downgrade Morgan Stanley Overweight → Equal-Weight $210 → $178
Mar-01-22Initiated Citigroup Buy $223
Jun-05-23 04:00PM
Jun-01-23 06:22AM
May-26-23 04:55PM
May-22-23 12:01PM
May-20-23 10:50AM
02:59PM Loading…
May-09-23 02:59PM
May-05-23 03:44PM
May-04-23 09:15AM
May-03-23 04:00PM
Apr-27-23 01:52PM
10:02AM Loading…
Apr-26-23 08:18PM
Apr-24-23 03:55PM
Apr-20-23 10:03AM
Mar-30-23 11:30AM
Mar-21-23 01:30PM
Mar-13-23 03:29PM
Mar-09-23 07:00AM
07:00AM Loading…
Mar-08-23 07:00AM
Mar-01-23 08:00AM
Feb-28-23 10:01AM
Feb-25-23 11:44AM
Feb-24-23 08:58AM
Feb-23-23 09:15AM
Feb-22-23 10:28AM
Feb-21-23 08:00AM
Feb-16-23 10:01AM
Feb-13-23 12:49PM
Feb-07-23 07:48PM
Feb-02-23 10:00AM
Jan-13-23 07:32PM
Jan-09-23 01:22PM
Jan-08-23 06:00PM
Jan-06-23 05:39AM
Jan-05-23 04:00PM
Jan-04-23 12:20PM
Jan-03-23 07:33PM
Dec-22-22 05:41AM
Dec-21-22 08:00AM
Dec-15-22 08:00AM
Dec-13-22 08:29AM
Dec-09-22 11:30AM
Dec-08-22 04:00PM
Dec-01-22 11:31AM
Nov-09-22 08:00AM
Nov-02-22 11:45AM
Oct-31-22 08:49AM
Oct-27-22 02:00PM
Oct-26-22 02:48PM
Oct-25-22 10:01AM
Oct-20-22 10:02AM
Oct-18-22 12:56PM
Oct-14-22 08:34AM
Oct-13-22 08:00AM
Oct-11-22 05:52AM
Oct-07-22 12:12PM
Oct-06-22 08:30PM
Oct-03-22 06:08AM
Sep-30-22 02:00PM
Sep-22-22 12:17PM
Sep-21-22 06:32PM
Sep-20-22 02:45PM
Sep-19-22 08:00AM
Sep-16-22 11:29AM
Sep-15-22 04:22PM
Sep-13-22 08:00AM
Sep-12-22 06:45AM
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Garg PushkalCMO & EVP Dev & Med AffairsApr 28Sale199.022,455488,5954,345Apr 28 05:54 PM
Greenstreet YvonneChief Executive OfficerApr 27Sale194.597,6151,481,81130,332Apr 28 05:55 PM
Vaishnaw AkshayPresidentApr 27Sale194.592,392465,46417,890Apr 28 05:54 PM
Garg PushkalCMO & EVP Dev & Med AffairsApr 27Sale194.591,839357,8556,800Apr 28 05:54 PM
Tanguler TolgaEVP, Chief Commercial OfficerApr 27Sale194.591,476287,2151,801Apr 28 05:55 PM
Poulton Jeffrey V.EVP, Chief Financial OfficerApr 27Sale194.59977190,11311,706Apr 28 05:55 PM
Franchini Indrani LallEVP, CLO & SecretaryApr 06Sale210.003,500735,0000Apr 10 04:29 PM
Garg PushkalCMO & EVP Dev & Med AffairsMar 03Option Exercise96.455,000482,25022,417Mar 07 04:07 PM
Garg PushkalCMO & EVP Dev & Med AffairsMar 03Sale200.0018,0723,614,4004,345Mar 07 04:07 PM
SCHULMAN AMY WDirectorFeb 23Option Exercise0.001360136Feb 27 04:13 PM
HAMBURG MARGARET ADirectorFeb 23Option Exercise0.001360136Feb 27 04:12 PM
PYOTT DAVID E IDirectorFeb 23Option Exercise0.001360136Feb 27 04:13 PM
Ausiello Dennis ADirectorFeb 23Option Exercise0.001360136Feb 27 04:11 PM
Fanucci MarshaDirectorFeb 23Option Exercise0.001360136Feb 27 04:11 PM
Tanguler TolgaEVP, Chief Commercial OfficerFeb 03Sale232.143,424794,8540Feb 03 05:45 PM
Franchini Indrani LallEVP, CLO & SecretaryFeb 02Sale226.011,675378,5633,500Feb 03 05:46 PM
Tanguler TolgaEVP, Chief Commercial OfficerFeb 02Sale226.011,601361,8393,424Feb 03 05:45 PM
Tanguler TolgaEVP, Chief Commercial OfficerFeb 01Option Exercise0.005,02505,025Feb 03 05:45 PM
Franchini Indrani LallEVP, CLO & SecretaryFeb 01Option Exercise0.005,17505,175Feb 03 05:46 PM
Vaishnaw AkshayPresidentDec 05Option Exercise59.055,079299,93823,425Dec 07 04:09 PM
Ausiello Dennis ADirectorNov 21Option Exercise71.0922,5001,599,63822,500Nov 23 04:05 PM
Ausiello Dennis ADirectorNov 21Sale220.0022,5004,950,0000Nov 23 04:05 PM
SHARP PHILLIP ADirectorAug 15Option Exercise33.7733,6701,137,06633,670Aug 17 04:07 PM
SHARP PHILLIP ADirectorAug 15Sale230.4933,6707,760,7360Aug 17 04:07 PM
Tanguler TolgaEVP, Chief Commercial OfficerAug 05Sale218.161,841401,6300Aug 05 04:15 PM
Tanguler TolgaEVP, Chief Commercial OfficerAug 03Sale210.001,754368,3403,629Aug 05 04:15 PM
Tanguler TolgaEVP, Chief Commercial OfficerJul 05Sale150.001,754263,1001,754Jul 07 04:06 PM